Bio-pharma has cut nearly 8,000 jobs in 2026 — and counting. Where the contractor opportunities are,…
SPECIAL REPORT
From lab bench to boardroom, bio-pharma is restructuring on a scale not seen since the pandemic boom. Factories are closing. R&D teams are being gutted. However, behind every redundancy announcement lies a problem…